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In February 2009, AndrewWitty, the Chief Executive of GlaxoSmithKline (GSK) announced that
GSK would slash the prices of its medicines in low-income countries, and, more surprisingly,
raised the idea of a patent pool, where holders of intellectual property rights would share
discoveries in order to stimulate neglected diseases research (Lancet, 2009; McNeil, 2010). The
announcement generated cautious praise from non-governmental organizations (NGOs) such as
the Me´dicins Sans Frontie`res (MSF) and the Drugs for Neglected Diseases Initiative, the latter
suggesting that GSK has emerged as the ‘most innovative’ pharmaceutical company to tackle the
persistent problem of how to encourage the private sector to pour R&D funding into diseases
that have little market value, as most sufferers are unable to afford the cost of treatments.
Staff at MSF welcomed the announcement – but stressed a number of problems. First,
GSK refused to endorse the possibility of pooling patents for HIV drugs, still priced beyond
the means of most HIV sufferers in low-income and developing countries. Second, even
GSK’s voluntary price reduction – Witty promised that medicines in poor countries would
be sold at no more than a quarter of their price in developed regions – is unlikely to lower
prices as dramatically as allowing more generic competition, which is increasingly limited
through stringent trade rules. Third, the idea of a patent pool hardly originated with Witty
or GSK. Staff at Unitaid, an international initiative that uses an airline ticket tax to fund
accelerated access to HIV, malaria and tuberculosis treatments, had been campaigning for
a patent pool for years, suggesting GSK might have been claiming publicity and praise for
an idea that was hardly novel (Lancet, 2009; see also Lexchin, 2010).
Behind the apparent selflessness of GSK’s strategy lies much contestation and controversy
over the economic motivations and unintended consequences of recent attempts to address
disparities in access to medicines and health care. Using the complex matrix of global
health initiatives as an anchor, contributors to this special issue explore the underlying
contention behind actions such as GSK’s, examining how industry moves such as price-
slashing in developing regions and calls for patent sharing relate to wider concerns about
the tensions between private and public investment in health care; the nature of what Marcel
Mauss once referred to as the ‘in fact obligatory and interested’ character of philanthropy
and gift-giving; and the national security objectives embedded in bilateral and multilateral
global health initiatives (Lakoff and Collier, 2008; Mauss, 1990).
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Global health is a field marked by an increasingly heterogeneous group of health actors,
many of which have overlapping and occasionally incommensurate aims. Over the past
20 years, global health has experienced ‘revolutionary’ changes (Fidler, 2008), with a
constellation of factors contributing to an explosion of political interest and economic
funding for global health aims. Such factors include, firstly, the increased recognition that
unstable patterns of global health pose unprecedented national security challenges, making
better health an explicit aim of Western governments. Where governments once tended to
underplay the extent to which national priorities were driving international investment
decisions, global health is marked by new openness on the part of Western governments
increasingly vocal that investment in global health is rooted in domestic security pressures.
This newfound openness may be oriented to stressing to the US public (increasingly shying
from support for interventionist foreign policy) that their safety depends on improving
global health conditions.1
A second factor is the influence of a public movement surrounding patent policies, and
specifically the reaction to the WTO’s trade-related aspects of intellectual property rights
(TRIPS) agreement, which continues to impede governments from importing or manufactur-
ing cheap generics, a limitation that received its strongest public censure when a consortium
of pharmaceutical companies sued the South African government for disseminating cheap
antiretrovirals to its HIV/AIDS sufferers. As Melinda Cooper points out, the emergence of
TRIPS, which began as a ‘brainchild of an extremely small group of private lobbyists,
united together as the Intellectual Property Committee (IPC), all of whom were CEOs in
the North American pharmaceutical, software, and entertainment industries’, needs to be
situated within the shifting contours of international geopolitical relations (Cooper, 2008,
p. 55; see also Correa, 2006).
TRIPS has been as much a political statement as it is an economic policy, helping
to immortalize patent law as the example par excellence of what economists and sociologists
from Schumpeter and Polanyi onward have described as the political nature of free markets;
the reality that keeping goods ‘freely’ circulating is always a matter of careful political
orchestration and intervention.2 From the standpoint of geopolitics, as Cooper notes, the
negotiation of TRIPS can be seen as a pre-emptive strike against the post-Cold War
economic ascendancy of non-G8 nations such as India, helping to calm North American
fears that cheap drug production in developing regions might pierce the bubble surrounding
artificially inflated drug prices in the West (Cooper, 2008).
A third and related factor increasing the prominence of global health has been growing
public attention to the devastating effects of the AIDS epidemic in sub-Saharan Africa, as
well as high-profile attention to campaigns to eradicate malaria and roll back tuberculosis,
the latter attracting much public bewilderment among Western citizenries shocked that
1 See, for example, a speech by Hilary Clinton inaugurating the US-led Global Health Initiative at a lecture at
the School of Advanced International Studies in August 2010, where she stressed that the ‘destabilizing
impact of AIDS led the Clinton Administration to categorize it not just as a health threat but a national
security threat, a position later echoed by then Secretary of State Colin Powell’, http://www.state.gov/
secretary/rm/2010/08/146002.htm.
2 See Chapter 8 of Schumpeter’s Capitalism, Sociology and Democracy, which provides a useful overview of
how, as Brenner puts it, ‘corporations routinely ensure the returns on their investments...by securing, by
all sorts of political-institutional means, the (temporary) protections of their markets from competition’
(Schumpeter, 1976; Brenner 1998, p. 31).
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curable diseases still kill millions annually. Political will for combating the ‘big three’
diseases targeted by Northern donors had led some health activists and experts to lament
that disproportionate funding towards HIV/AIDs and to a lesser extent malaria and
tuberculosis may be detracting from funding of research on chronic diseases (such as obesity,
a growing cause of death globally) and less publicized high-mortality afflictions such as
diarrhoea (see Sridhar and Batniji, 2008). Tensions over which diseases are prioritized by
donors, and whether the aims of donors are aligned with the needs of recipients, have been
exacerbated by the fourth major factor contributing to the radical overhaul over global
health from the early 1990s onward: the emergence of new philanthropic donors focused on
global health, and specifically the Bill and Melinda Gates Foundation.
Although global health experts and activists are becoming more and more divided about
the advantages and disadvantages of the Gates Foundation’s growing role in directing
international health policies, as Kelly and Beisel (this volume) explore, there is little debate
about one fundamental aspect of its emergence: the sheer magnitude of spending has been
the greatest change in global health in past decades, dwarfing the contributions of most
national governments, and radicalizing the budgetary compositions of UN agencies such as
the WHO, which obtains a significant portion of its budget from the Gates Foundation
(McCoy et al, 2009).3 The scale of funding for recent initiatives and the stabilization and
institutionalization over the last decade or so of this field of ‘global health’ raises a number
of questions. How, if at all, is global health different from other configurations of health?
What are global health interventions perceived as a response to? What are some of the
effects and unintended consequences of such interventions?
To begin with, we might say that the global health move has opened up a worldwide
epidemiological and demographic problem space within which disease burdens, distribu-
tions, movements and causes are mapped out and rendered problematic. Andrew Lakoff
has traced the contours of what he calls two ‘regimes of global health’, namely global
health security and humanitarian biomedicine which both aim to ‘transcend certain
limitations posed by the national governance of public health’ (Lakoff, 2010). If global
health security is centred around efforts to foresee, prevent, track and tackle outbreaks
(for example, SARS or ‘swine flu’) primarily in more well-off nations, then humanitarian
biomedicine is centred on efforts to treat and prevent diseases that afflict individuals in
poorer nations of the world (for example, malaria, tuberculosis as well as a range of
so-called ‘neglected diseases’) where resources are meagre. It is primarily with this latter
regime and the many inequities it encompasses that articles in this special issue engage.
Neglect as a Matter of Prioritization
Although recent dramatic changes in global health funding and governance have attracted
growing scholarship, much of it has come from those working in international relations,
3 The growth in funding for global health in recent years has been dramatic. The World Bank estimates
governmental development assistance for health grew from US$2.5 billion in 1990 to US$14 billion in
2005, while private donations – something difficult to chart as global tracking and monitoring mechanisms
are notoriously limited – are estimated to have spent US$1.6 billion on global health in 2005, with the bulk
of funding from the Gates Foundation (see McCoy et al, 2009, Sridhar, 2009).
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international political economy and public policy (cf. Lee et al, 2002; Buse and Harmer,
2004; Kickbusch, 2006; Sridhar, 2009), and there has been comparatively less attention
within fields such as anthropology and sociology to how new philanthropic players and
global health partnerships are affecting the prioritization of different global health policies
over others. Articles in this volume contribute to a small but growing body of scholarship
working at the intersections of science and technology studies, philosophy of science, critical
sociology and anthropology and development studies that have begun to explore the cultural
and epistemological implications of recent shifts in power, accountability and governance
ushered in by the explosion of new private and public actors and resources in global health
institutions (cf. Peterson, 2001; Mosse and Lewis, 2005; Biehl, 2007; Ecks, 2008; Mahajan,
2008; Redfield, 2008; Reiss and Kitcher, 2009).
Attention to global health must grapple with a persistent problem, which is the fact
that, as Solomon Benatar points out, the recent explosion in funding for health has not
thus far diminished global health inequalities. Indeed, the opposite is true: ‘Disparities in
wealth and health within and between nations continue to widen inexorably (the world is
more inequitable than 50 years ago)’, writes Benator in a recent article enumerating familiar
statistics about widening health gaps across the globe. ‘Life expectancy at birth ranges
from well over 70 years (and rising) in highly industrialized countries to below 50 years
(and falling) in many countries. In sub-Saharan Africa gains in life expectancy achieved
during the first half of the 20th-century are rapidly being reversed by the HIV/AIDS
pandemic’ (Benatar, 2009, p. 2).
It is against this backdrop of health inequalities and health funding that questions
of prioritization become charged and contested. As Jeremy Greene (this volume) shows in
his historical account of the making of the WHO’s Essential Medicines List, although the
notion of an ‘essential medicine’ emerged out of wartime scarcities and logistical difficulties
in the mid-twentieth century, despite several high level committees, reports and analyses, it
has proved difficult to agree on what particular criteria should be used to define what is
essential when it comes to medicine. The ‘essential medicine’ concept is contested by often
conflicting commercial, humanitarian, epidemiological and logistical concerns.
Another list which brings the question of prioritization to the fore is that of so-called
‘neglected diseases’. These are often described as tropical diseases which afflict people
predominantly in poorer parts of the world (where the majority of the world’s population
live) yet receive scant attention (from researchers, pharmaceutical companies, NGOs, and
so on) when compared, for example, to ‘diseases of the rich’. Yet, as Alex Broadbent shows
(this volume), we must carefully examine the epistemological grounds of classification
which make possible the drawing up of such lists. If, as he puts it, neglected diseases are ‘a
group of diseases which, according to whoever is drawing up the list, do no not receive
adequate attention, in some sense’, then it is important to understand what a ‘disease’ is,
which ways it is not receiving attention, and how to determine what is sufficient attention.
Broadbent argues against embracing multifactorial definitions of disease to prevent
dilutions of the pool of ‘neglected diseases’. In the context of humanitarian biomedicine, an
important point to be made is that every prioritization will come at the neglect of another,
and that there are many dimensions of ‘neglect’ including: prioritization of certain diseases
over others in laboratory-based disease research; prioritization of certain avenues of re-
search over others when it comes to a particular disease or group of diseases (for example,
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pharmaceutical, genomic, field trials, public health approaches); prioritization of certain
disease definitions over others (for example, biological pathology, socio-economically
determined, multifactorial); and prioritization of disease research over public health and
development initiatives. Neglect implies that other options have been chosen instead. Should
disease be tackled as a pharmaceutical, genomic, socio-economic or public health problem?
Is it possible to get the balance right?
Failures of Pharmaceutical Solutions
What becomes clear in many of the contributions to this volume is how predominant
and problematic pharmaceutical solutions to global health problems have become over
the last decades. Debates around essential medicines and neglected diseases are for the
most part pharmaceutical in orientation: how to improve access to pharmaceuticals in
poorer parts of the world? How to encourage pharmaceutical companies to develop drugs
for neglected diseases?
Donald Light’s (this volume) and Anne Pollock’s (this volume) articles provide important
background information for assessing whether and to what extent solutions for neglec-
ted diseases can (or should) come from the pharmaceutical industry. Light analyses the
risks and costs of neglected disease research and argues that both are significantly lower
than often claimed or feared. With lower research risks and costs, pharmaceutical companies
have fewer excuses not to engage in humanitarian biomedicine without having to be
motivated to do so by so-called advance market commitments, which, Light argues, are
both expensive and impractical for incentivizing research into neglected diseases.
Pollock sees ‘Big Pharma’s’ current business model challenged by the external pressures
of failures of would-be blockbusters, patent expiration, competition from both small biotech
companies and philanthropy, and pricing guidelines from health assessment bodies such
as the UK’s National Institute for Health and Clinical Excellence. Rendered vulnerable by
its own previous strategies and production tactics, she suggests Big Pharma is reinventing
itself in ways that requires STS scholars and anthropologists of science and medicine to
nuance their own analyses of this industry. We need more sensitivity, she suggests, to the
creative ways that companies might appear to undercut their own competitiveness (that
is, through creating in-house generic divisions and price-slashing in poor regions) in order
to meet longer-term goals, such as the exploitation of untapped markets and the cultivation
of public regard through high-profile gestures of good will. In Pollock’s words, we need
to examine how a matrix of global philanthropists (for example, Bill Gates, Bill Clinton)
and global pharma have commanded the posture of the humanitarian, ‘even as they grasp
ever more territory for their models of capitalism’.
Broader Biosocial Approaches
The pharmaceuticalization of humanitarian biomedicine (see also Biehl, 2007) has in many
ways overshadowed other attempts at addressing health inequalities in poorer parts of
the world. Paul Kadetz (this volume) critically examines recent attempts to integrate
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traditional medicine into national health delivery systems in the Philippines as a way to
improve access to health care. Rather than improving access to medicines, such globally
sponsored programmes focus on improving the provision of health care in resource-poor
settings by enlisting traditional practitioners in a project of national health delivery.
Kadetz argues that although the drive to integrate is underwritten by assumptions of
beneficence – that is, especially poor persons will benefit from integration – the effects
of integration programmes are not necessarily always positive. Through a series of
interviews with informants in four municipalities and 16 communities, he concludes
that integration programmes do not appear to increase physical and financial access
to health care, and in fact might even hamper access in the case of traditional birth
attendants who are discouraged from attending births if they haven’t received certain forms
of training. As such, what should be kept firmly in mind is that each avenue or priority
chosen when it comes to treating health needs – whether pharmaceutical or non-
pharmaceutical in orientation – has distinct logistics, challenges and effects.
The link between development and health is also highlighted in Ann Kelly and Uli
Beisel’s (this volume) account of how the local realities of malaria prevention efforts are
neglected by global health programmes championed by philanthropic bodies such as the
Gates Foundation. Many of the diseases and conditions that are considered ‘neglected’ in
the context of global health today are found ‘where the pavement ends’. In their article, we
are shown how the Gates Foundation’s ‘audacious goal’ to eradicate malaria once and for
all rests on a version of malaria that is seen as ‘produced by the lack of knowledge, money
and will’. By detailing mundane field efforts to investigate the efficacy of microbial
insecticide by researchers with the Urban Malaria Control Program in Tanzania, Kelly and
Beisel argue that the ‘technological emphasis of current malaria research – on vaccines,
combinational therapies or genetic control – simply does not suit its object. Malaria is
not static; it is an evolving vector between human habits and mosquito habitat’. There is
a larger point to be drawn from their article, namely that the predominance of techno-
logical approaches to improving access to medicine and health care in humanitarian
biomedicine today have come at the neglect of other possible approaches (see also
Birn, 2005).
Outlook
As this volume shows, some advances have been made but enormous challenges lie
ahead. Much recent literature has targeted the pharmaceutical industry and its search
for patentable solutions for neglected diseases (see, for instance, Pogge, 2005; Hollis and
Pogge, 2008). But there are doubts that multinationals are the right target for encourag-
ing sustainable pricing policies, and whether patentable solutions always work best. Even
the fact that, as Light points out, costs and risks or drug development are much lower than
the pharmaceutical industry would have us believe, many big players in the industry are still
not interested in research into diseases of the poor, and this is unlikely to change, however
great the incentive. One recent report into neglected disease research concluded, ‘[Multi-
national pharmaceutical companies] believed that additional new incentives were unlikely to
shift the behaviour of firms who had disengaged from neglected disease research, and saw
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the main role for any new incentives as being “to support companies who had already
decided to do neglected disease R&D for other reasons” ’ (Pharmaceutical R&D Policy
Project, 2005, p. 13).
A second limitation of encouraging the pharmaceutical industry’s benevolence is the
dilemma of bolstering industry efforts to divert attention from unethical marketing and
drug development practices by publicizing the philanthropic activities of the same compan-
ies consistently engaged in tactics contrary to health aims. GSK, which recently achieved,
as Greene’s article (this volume) points out, the position of #1 on the global Access
to Medicines Index for efforts to improve neglected disease financing, was just as recently
censured by UK drug regulators for failing to disclose clinical trials where more children
were harming themselves on Seroxat, its bestselling antidepressant drug, than on comparator
treatments (see McGoey and Jackson, 2009). Currently, the company is test-
ing the same drug, banned for use in under-18s by European and UK authorities, in
children as young at seven in Japan (Clinicaltrials.gov, 2010; see Edwards, 2010).
Novartis, as Stefan Ecks (2008) explored, secured a financial coup even as it appeared
to lose a high-profile battle over the patenting of Glivec, its bestselling cancer drug. In
2007, Novartis launched a legal suit against a number of Indian governmental bodies after being
denied a patent for a second version of Glivec, copies of which had been manufact-
ured for a fraction of Glivec’s brand price by generic firms. Throughout the suit, Novartis
highlighted the fact that it distributes Glivec to many Indian sufferers at no cost through
its International Patient Assistance Program (GIPAP), a programme fundamental to Novartis’s
widely publicized efforts to increase access to medicines in developing regions. Ecks highlights a
number of reasons why Novartis might donate Glivec freely. First, the effort to undercut
competing Indian versions. Second, the effort to develop a lobby of Indian civil society actors
vocal about Novartis’ positive influence in the region, something akin to corporate funding of
patient advocacy groups in theWest. Novartis didn’t merely undercut competition, however; they
undercut their own profitability in India – something that only makes economic sense once it
becomes clear the Indian market was never the key market at stake.
Selling Glivec at the cost of generic prices risks something Ecks, drawing on work by
the economist Sudip Chaudhuri, describes as two ‘leakages’: economic and informational:
‘On the one hand, they fear a “physical leakage” of drugs from low-price to high-price
markets. On the other, “they may actually be more worried about the information
spillovers – the knowledge about lower prices in developing countries generating demand
for lower prices in developed ones” ’ (Chaudhuri, quoted in Ecks, 2008). In other words,
corporate philanthropy in the South does not merely generate symbolic capital in North,
increasing public perceptions of pharma companies as good global citizens, it serves the
economic objective of deflecting attention from pricing bubbles in rich regions, bubbles
which are growing more fragile as wealthy nations such as Germany and China move
to implement stricter price controls on pharmaceutical products (Taylor, 2010).
Developments explored in this issue – the push for patentable solutions; the wide publicity
for philanthropic gestures that often offer merely cosmetic solutions – suggest that the
fervour for pharmaceutical solutions may be undermining efforts to strengthen health
systems. It is clear that pharmaceuticals will always have a place when addressing global
health problems, what is less clear is what an optimal role for pharmaceuticals and their
multinational producers might be. Processes of pharmaceuticalization and commercialization
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are problematic not because of (the development of) pharmaceuticals per se, but rather they
become problematic within political arenas of prioritization, production, distribution and
(mis)use.
It is somewhat heartening, then, that global health concerns are increasingly on the radar
of social scientists attuned to studying both explicit and tacit institutional pressures – both
political and economic – that risk privileging short-term or cosmetic responses at the expense
of structural change. The authors of the articles in this volume have affiliations in
departments of anthropology, development, geography, history of science, philosophy,
public health and science studies. This diversity gives reason for mild optimism that the
pharmaceuticalization of global health is not without sustained scrutiny, and in some cases,
vibrant resistance.
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